Jeff M Michalski
Overview
Explore the profile of Jeff M Michalski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
195
Citations
5057
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nikitas J, Jamshidian P, Tree A, Hall E, Dearnaley D, Michalski J, et al.
Lancet Oncol
. 2025 Feb;
26(3):378-386.
PMID: 39894025
Background: The association between acute and late toxicity following prostate radiotherapy has not been well studied using data from multiple randomised clinical trials and fractionation schedules. We aimed to characterise...
2.
Hansen A, Probst S, Beauregard J, Viglianti B, Michalski J, Tagawa S, et al.
Front Oncol
. 2025 Jan;
14():1483953.
PMID: 39839782
Introduction: SPLASH (NCT04647526) is a multicenter phase III trial evaluating the efficacy and safety of [Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer (mCRPC). This study leveraged a lead-in phase...
3.
Patel S, Patil D, Smith J, Saigal C, Litwin M, Hu J, et al.
JAMA Netw Open
. 2024 Oct;
7(10):e2440747.
PMID: 39446326
Importance: The association between radiotherapy (RT) timing after radical prostatectomy and long-term patient-reported health-related quality of life (HRQOL) in men with prostate cancer is unknown. Objective: To measure long-term HRQOL...
4.
Wisdom A, Yeap B, Michalski J, Horick N, Zietman A, Christodouleas J, et al.
Int J Radiat Oncol Biol Phys
. 2024 Oct;
121(3):741-751.
PMID: 39357788
Purpose: Men with localized prostate cancer may receive either photon-based intensity modulated radiation therapy (IMRT) or proton beam therapy (PBT). The PARTIQoL trial (NCT01617161) demonstrates the feasibility of performing a...
5.
Momodu J, Carvajal C, Pryma D, Anie H, Michalski J, Yom S, et al.
Int J Radiat Oncol Biol Phys
. 2024 Oct;
120(4):931-935.
PMID: 39352323
No abstract available.
6.
Dahl D, Rodgers J, Shipley W, Michaelson M, Wu C, Parker W, et al.
J Clin Oncol
. 2024 Sep;
42(34):4095-4102.
PMID: 39226514
Purpose: To investigate the use of radiation with radiosensitizing chemotherapy following repeated transurethral resection (trimodality therapy) as an alternative to radical cystectomy in T1 bladder cancer which has failed Bacillus...
7.
Kuo P, Morris M, Hesterman J, Kendi A, Rahbar K, Wei X, et al.
Radiology
. 2024 Aug;
312(2):e233460.
PMID: 39162634
Background Lutetium 177 [Lu]Lu-PSMA-617 (Lu-PSMA-617) is a prostate-specific membrane antigen (PSMA)-targeted radioligand therapy for metastatic castration-resistant prostate cancer (mCRPC). Quantitative PSMA PET/CT analysis could provide information on Lu-PSMA-617 treatment benefits....
8.
Lowentritt B, Jani A, Helfand B, Uchio E, Morris M, Michalski J, et al.
Adv Radiat Oncol
. 2024 Aug;
9(8):101532.
PMID: 39104875
Purpose: F-Flotufolastat (F-rhPSMA-7.3) is a newly approved prostate-specific membrane antigen targeting radiopharmaceutical for diagnostic imaging of prostate cancer (PCa). SPOTLIGHT (National Clinical Trials 04186845) evaluated F-flotufolastat in men with suspected...
9.
Sartor O, Karrison T, Sandler H, Gomella L, Amin M, Purdy J, et al.
Eur Urol
. 2024 Jun;
86(3):289-290.
PMID: 38897867
Background: Intensification of therapy may improve outcomes for patients with high-risk localized prostate cancer. Objective: To provide long-term follow-up data from phase III RTOG 0521, which compared a combination of...
10.
Wang D, Geng H, Gondi V, Lee N, Tsien C, Xia P, et al.
Cancers (Basel)
. 2024 Jun;
16(11).
PMID: 38893130
The quality of radiation therapy (RT) treatment plans directly affects the outcomes of clinical trials. KBP solutions have been utilized in RT plan quality assurance (QA). In this study, we...